<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538121</url>
  </required_header>
  <id_info>
    <org_study_id>MHST2012-01A</org_study_id>
    <nct_id>NCT01538121</nct_id>
  </id_info>
  <brief_title>Antiphospholipid Antibodies and Early Severe Preeclampsia.</brief_title>
  <official_title>Antiphospholipid Antibodies and Early Severe Preeclampsia (&lt; 34 Weeks of Gestation). A Case-Control Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Thomas Hospital, Panama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Thomas Hospital, Panama</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed
      against cell membrane phospholipids (antiphospholipid antibodies) can cause an
      hypercoagulable state that causes thrombosis and obstetric complications (miscarriages,
      stillbirths). Since 1999 the Sapporo Criteria for Antiphospholipid Syndrome diagnosis
      includes the development of severe preeclampsia before 34 weeks of gestation, but this was
      done without solid evidence of a relation between the two. Our study will try to add
      information to this particular point.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lupus anticoagulant</measure>
    <time_frame>15 months</time_frame>
    <description>Number of cases positive for Lupus Anticoagulant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anticardiolipin antibodies</measure>
    <time_frame>15 months</time_frame>
    <description>Number of cases with high/medium levels of IgG/IgM of anticardiolipin antibodies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>B2 Glycoprotein I</measure>
    <time_frame>15 months</time_frame>
    <description>Number of cases with levels of B2 Glycoprotein 1 &gt; 99%</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Severe Preeclampsia</condition>
  <condition>Antiphospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>Cases-Early Severe Preeclampsia</arm_group_label>
    <description>Patients with severe preeclampsia before 34 weeks of gestation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Patients with normal pregnancies at term.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant patients admitted for severe preeclampsia between 24-34 weeks pf gestation (cases)
        and normal patients in labor at term (controls).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age between 24-34 weeks

          -  Diagnosis of severe preeclampsia

        Exclusion Criteria:

          -  Known antiphospholipid syndrome.

          -  Known presence of antiphospholipid antibodies.

          -  Patients with systemic lupus erythematosus.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osvaldo A Reyes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Thomas Hospital, Panama</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Thomas Maternity Hospital</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2012</study_first_submitted>
  <study_first_submitted_qc>February 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2012</study_first_posted>
  <last_update_submitted>January 1, 2015</last_update_submitted>
  <last_update_submitted_qc>January 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Thomas Hospital, Panama</investigator_affiliation>
    <investigator_full_name>Osvaldo A. Reyes T.</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Antibodies, anticardiolipin</keyword>
  <keyword>Antibodies, B2 Glycoprotein I</keyword>
  <keyword>Lupus Anticoagulant</keyword>
  <keyword>Severe Preeclampsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Antiphospholipid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

